Hazelnut resistance evidence from New Jersey
The New Jersey field trials combined deliberate EFB exposure with natural spread and used no chemical disease control.1
All tested Gasaway-carrying trees in the 2019 planting developed EFB; most developed severe disease.1
Some Ratoli-derived selections developed EFB in the 2019 planting, while another remained symptom-free in the 2017 planting.1
Use this evidence when selecting stock
Editorial application: ask for evidence about the exact cultivar, disease population, site and evaluation period. Distinguish a breeding parent or resistance source from the performance of its individual descendants. Neither this study nor a genetic label supplies a complete nursery recommendation, compatible donor pair or production forecast.
For European hazelnut, compare the current Pacific Northwest update with regional observations. The Lagerstedt lead in that update is not established by the results here: do not assign it a tested response merely because it shares a named resistance source. Conversely, the observed disease in other descendants does not prove Lagerstedt will fail at a proposed site.
For a grower, the next action is to obtain locally relevant cultivar evidence and a management plan before purchase. For an existing tree, retain cultivar identity and investigate symptoms using the EFB guide; lack of visible symptoms on an inspection is not a proof of durable resistance. Keep any subsequent observations separate from the published trial outcomes.
This disease study does not establish nut quality, yields, winter hardiness, pollen overlap, planting density or container suitability. Its challenge-plot methods are not planting instructions. Inspection scope and unresolved details.